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Abstract
Background: Despite the fact that the cost-effectiveness of robot-assisted radical cystectomy (RARC) is not yet
proven, and open radical (ORC) cystectomy is recommended as the standard of care in patients with high-risk
non-muscle-invasive and muscle-invasive bladder cancer, the use of RARC is still increasing. The objective of
the current ongoing comparative effectiveness trial therefore is to study the (cost-)effectiveness of RARC
compared to ORC, both in terms of objective (complication rates, oncological outcomes) and patient-reported
(health-related quality of life) outcome measures.
Methods: This study is designed as a non-randomized, multicentre comparative effectiveness trial.
Centres with an annual caseload of > 20 radical cystectomies can include patients after informed consent has
been given. Centres that perform RARC must have passed the (initial) learning curve of 40 cases. A total of
338 (2 × 169) patients will be enrolled from 23 participating centres (12 ORC, 10 RARC and 1 LRC). Follow-up
visits will be scheduled at 1, 3, 6 and 12 months. During each follow-up visit, clinical data and health-related
quality of life questionnaires will be administered. Costs will be studied using a monthly resource usage
questionnaire. Impact on complications and quality of life will be calculated as the average difference
between the groups with 95% confidence intervals, adjusted for potential baseline differences by means of
propensity score matching.
Discussion: This study aims to contribute to the development of evidence-based guidelines regarding the
most cost-effective surgical technique for radical cystectomy.
Trial registration: Nederlands Trial Register/Dutch Trial Registry, trial identifying number: NTR5362. Registered
on 14 August 2015. (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5362).
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Background
Radical cystectomy with pelvic lymphadenectomy and
urinary diversion is the standard of care for both
high-risk non-muscle-invasive bladder cancer and
muscle-invasive disease [1]. This surgery is complex and
associated with considerable postoperative morbidity, in-
cluding major and minor complications with probabil-
ities ranging from 13 to 67% [2–6]. Complications may
lead to extra costs, prolonged hospital stay, additional
interventions, a reduced quality of life, and a longer time
before patients may return to normal activities.
Currently, there are two main surgical techniques to
perform a radical cystectomy: robot-assisted (RARC) and
open surgery (ORC). ORC is the recommended treatment
according to European guidelines, but RARC has been
suggested to improve the perioperative morbidity without
compromising oncological efficacy, and the percentage of
hospitals and surgeons performing RARC is increasing
steadily [7]. For example, 11 out of 69 (14.4%) Dutch cen-
tres performed RARC in 2014, and in 2016 24% of all rad-
ical cystectomies were performed robot assisted [8]. In the
USA, the use of robot assisted technique has increased
from 1% in 2004 to 13% in 2010 [9]. High-level evidence
of methodologically sound clinical studies that compare
both treatments is, however, lacking. Furthermore, direct
costs of robotic surgery are expected to be higher than for
open surgery, so investment in this technology can only
be justified when additional costs are balanced by a signifi-
cant benefit regarding patient outcomes.
Existing knowledge
At the time we designed this study (2015), two systematic
reviews (both including 105 studies) had been reported.
[2, 10] Novara et al. reported on perioperative outcomes
and complications after RARC, whereas Yuh et al. re-
ported on oncologic and functional outcomes after RARC.
Ninety-three of the 105 studies reported perioperative
outcomes and complications of RARC; including 23 com-
parative studies and 70 surgical series. Most of the surgical
series were retrospective single centre studies and only
three randomized trials were found.
The overall results showed shorter operative time for
ORC, whereas blood loss and hospital stay were better
with RARC. Moreover, 90 day complication rates of any
grade and grade 3 complications were lower for RARC,
whereas high-grade complication and mortality rates were
similar [2] Analyses showed no significant difference be-
tween RARC and ORC in lymph node yield and rates of
positive surgical margins [10]. Very limited data were
available with respect to functional outcomes and quality
of life. According to both authors, the most relevant limi-
tations of their systematic reviews were the quality of the
included studies, the small study populations, the retro-
spective nature of most series, the short follow-up period,
and the lack of standardized definitions [2, 10]. This lack
of methodologically sound data precludes a definite con-
clusion about the effectiveness of RARC versus ORC.
Up to now, four randomised trials [11–14] have been re-
ported and two others are ongoing (RAZOR [15] and
iROC (ClinicalTrials.gov identifier: NCT03049410). Shen
et al. [16] performed a meta-analysis of these 4 RCT’s
[11–14] and presented evidence for a benefit of estimated
blood loss, time to diet, similar perioperative complica-
tions and oncological outcomes, but a longer operative
time in RARC. Furthermore, in the largest trial [13] sur-
geons performing RARC were still in their learning curve,
and another trial only included 20 patients per arm and
potential surgeon bias (i.e. there was a different surgeon
for each technique) could not be precluded [14].
The two ongoing trials, i.e. RAZOR [15] and iROC, com-
prise multi center trials. RAZOR is a multi-institutional, ran-
domized, non-inferiority, phase III trial, which aims to enrol
320 patients from 15 participating centres in the USA. They
will study oncological outcomes, complications and quality
of life of RARC compared to ORC. The primary endpoint is
progression-free survival after 2 years. A potential limitation
of the RAZOR trial might be the RARC learning curve, as
surgeons must have performed only more than 10 RARCs
in the past year. The learning curve of RARC is, however,
estimated to be between 16 and 30 cases [17–19]. iROC is a
prospective multicentre randomised controlled trial compar-
ing the outcomes of intracorporeal RARC (iRARC) with
ORC, which aims to enroll 320 patients. The primary out-
comes (functional recovery and return to normal activities)
will be measured 90 days post-surgery.
Need for a comparative-effectiveness trial
As described above, all trials performed so far have been
limited by sample size and design, or by their application of
RARC with extra-corporeal reconstruction. We have
chosen for a comparative effectiveness study since observed
effectiveness will depend on the complex decision-making
process of clinicians selecting therapies, their experience
with the technique under study, and on the decisions and
actions of patients, including whether they accept or prefer
a certain surgical technique. The impact of these issues on
effectiveness may be difficult or impractical to assess in a
traditional RCT, in which treatment assignments are ran-
domized and may therefore lead to a bias due to the expert-
ise of the surgeons in a center.
Objective
The objective of the current ongoing comparative-
effectiveness trial is to study the effectiveness of RARC
as compared to ORC in patients with bladder cancer
and an indication for radical cystectomy in terms of
complication rates, health related quality of life, and
disease free survival.
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Methods
Design
This study is designed as a non-randomized, multicentre
comparative effectiveness trial. Patient recruitment is
currently being conducted at urology outpatient clinics
in five academic tertiary referral centres and eighteen re-
ferral centres in the Netherlands. A multicentre ap-
proach was chosen to obtain the desired power and to
assure representativeness of our sample to the target
population. Each centre will perform either RARC or
ORC. Centres that perform both RARC and ORC can
only participate if they do not select a technique based
on patient characteristics, other than described in the
exclusion criteria. Only high volume centres (> 20 radical
cystectomies per year) can participate in the study. To
prevent learning curve bias, only centres that have per-
formed at least 40 RARCs can participate.
Characteristics of participants
Inclusion criteria
Patients eligible for the trial must comply with all of the
following:
1) Eighteen years or older.
2) Oncological indication for radical cystectomy.
3) Histologically proven primary muscle invasive
transitional cell carcinoma or therapy resistant
high-risk non muscle-invasive bladder cancer (CIS,
refractory pTa-1).
4) Tumour is considered non metastatic (cT1a-cT4a,
N0 M0) at the time of inclusion. Patients with N+
status may receive neoadjuvant chemotherapy, but
can only be included in the study when
preoperative scans show N0.
5) Able to fill in Dutch questionnaires.
6) Provide written informed consent.
Exclusion criteria
When a patient meets one of the following exclusion cri-
teria, they will be excluded from participation:
1) Previous major abdominal surgery (i.e. existing
stomata, status after low anterior resection of the
rectum or rectal amputation, status after open
aortabifemoral graft, status after right
hemicolectomy).
2) Morbid obesity (BMI ≥ 40 kg/m2).
3) Radical cystectomy is performed in combination
with a nephrectomy or a partial colon resection.
4) Pregnancy.
Interventions
Overall, the surgical techniques for ORC or RARC are
standardized procedures. Radical cystectomy with pelvic
lymphadenectomy with diversion will be performed in
all cases. If the formation of a neobladder is oncologi-
cally safe and technically feasible, patients can choose
between an ileal conduit and a continent urinary diver-
sion (neobladder). For RARC, one centre performs an
extracorporeal technique, whereas all other centres per-
form a total intracorporeal reconstruction.
The peri-operative protocol has been standardized for
all participating centres, including a fast track (ERAS)
protocol. All centres are asked to follow the RACE-ERAS
protocol, based on the current international guidelines
and best available evidence. An identical protocol is used
for RARC and ORC, to prevent bias due to different peri-
operative protocols. Table 1 presents the RACE-ERAS
protocol used for this study.
Outcomes
Primary endpoint
The primary outcome measure comprises 90 days compli-
cations, according to the Clavien-Dindo classification [20].
Secondary endpoints
Secondary outcomes comprise perioperative morbidity and
mortality, 30 days and 1 year complications, health-related
quality of life, disease free survival, time to return to normal
activity, blood loss and transfusion parameters, operating
time, hospital and intensive care stay, oncological out-
comes, and costs.
Patient reported outcomes
Health-related quality of life is measured at baseline (pre--
operatively) and post-operatively at 1, 3, 6, and 12 months
using three quality of life questionnaires: Functional Assess-
ment of Cancer Therapy–Bladder cancer Cystectomy
(FACT-Bl-Cys, formerly FACT-VCI), Bladder Cancer Index,
and the 5-level version of the EuroQol 5D (EQ-5D-5 L).
The FACT-Bl-Cys questionnaire is a disease and
treatment-specific tool for assessing quality of life following
radical cystectomy and urinary diversion [21]. It includes
42 questions dealing with general domains (physical, social/
family, emotional and functional well-being) plus 17 add-
itional items covering urinary, sexual, and bowel function.
The Bladder Cancer Index is developed for patients who
are diagnosed with bladder cancer and covers a broad range
of health and quality of life, including three domains,
namely urinary, bowel and sexual functioning, containing
14, 10 and 12 items, respectively [22]. The EQ-5D-5 L con-
sists of a descriptive part and a visual analogue scale (VAS)
[23]. The descriptive part comprises the following five di-
mensions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. The VAS records the
respondent’s self-rated health on a vertical scale ranging
from 0 (worst imaginable health state) to 100 (best imagin-
able health state).
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Resource use will be assessed using the RACE healthcare
usage questionnaire, which is based on the iMCQ [24] (to
assess medical consumption such as hospital visits, medica-
tion use and domestic help) and the iPCQ (to measure ab-
sence from work due to illness) [25]. This questionnaire
will be completed at baseline (pre-operatively) and every
month afterwards. It records resource use, such as doctor’s
visits, medication, hospital admissions, and out-of-pocket
expenses such as over-the-counter drugs. Additionally, trav-
elling time to the outpatient clinic and related costs are
asked for. Where relevant, (missing) entries will be verified
by data from the medical records.
Clinical outcomes
Perioperative and postoperative measures (e.g. blood
transfusion rates, intraoperative fluid requirements, op-
erative time, length of hospital stay and analgesic re-
quirement) are prospectively recorded. Operating time is
defined as the skin-to-skin operating time in minutes,
not including anaesthetic preparations as these might
differ between the participating centres. Total operating
room occupation time is also measured.
Pathological data is obtained from pathology reports
after surgery with particular emphasis on surgical mar-
gin status, total number of lymph nodes removed and
their involvement with cancer, as well as pathological
stage of the tumour. A standardized form will be used to
collect all information pertaining to specimen processing
and staging by the participating institutions. In addition,
since centres are obliged to complete the national uro-
logic database, the Dutch Urological Association can
and will provide us with export files for each RACE par-
ticipant, which will subsequently be imported in the
eCRF (electronic Case Report Form).
Participant timeline
Timeline is depicted in Fig. 1. Treating urologists in the
participating centres will recruit patients that fulfil the
in- and exclusion criteria. Information is given about the
rationale and the design of the RACE study. Potential
participants will receive both the information letter and
the informed consent form. Patients will have sufficient
time to consider participation. If they agree to partici-
pate, informed consent will be signed. Once patients
signed informed consent, contact information will be
transmitted to the coordinating researcher. Patients will
be operated in their own centre within 4 to 6 weeks;
from the moment they signed informed consent.
Patients are asked to fill in 3 quality of life ques-
tionnaires at five different time points: before the
Table 1 ERAS protocol used for RACE study
Item Standard Optional
1. Pre-operative: extensive counselling patient ✓
2. Correction anaemia (Hb ≥ 6 mmol/l) ✓
3. Pre-operative consult dietary specialist ✓
4. Quit smoking ✓
5. Physical exercise before surgery ✓
6. Pre-operative enema: 12 h before surgery (in case of constipation) ✓
7. Pre-operative: High calorie fluids, until 2 h before surgery ✓
8. Pre-operative: solid food until 6 h before surgery ✓
9. Pre-operative: clear fluids, until 2 h before surgery ✓
10. Epidural analgesia (thoracal) until max 72 h after surgery ✓
11. Antibiotic prophylaxis, one-shot pre-operative
Cefazoline (≤80 kg 1 g; > 80 kg 2 g) + Metronidazole (500 mg). May be
repeated if the operation time is longer than the half-life
✓
12. Anaesthetic considerations
Normothermia, Goal directed fluid therapy, normovolemia, short acting
sedatives, minimalize opioids.
✓
13. Post-operative: nasogastric tube removed directly after surgery ✓
14. Post-operative: start laxantia post-op day 1 ✓
15. Post-operative: chewing gum ✓
16. Post-operative: standard anti-emetica ✓
17. Post-operative: start mobilisation 6 h after surgery ✓
18. Post-operative: fluid diet until first stool ✓
19. Post-operative: Thrombosis prophylaxis for four weeks with
‘low molecular weight heparin’ = LMWH (Fraxiparine 0,6 cc)
✓
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operation, and then 1, 3, 6 and 12 months after sur-
gery, which will take about ten minutes per question-
naire. In addition, patients are asked to fill in a cost
questionnaire monthly, which will take approximately
less than five minutes.
Clinical data are registered in a central validated
database (eCRF, Research Manager) by (local) re-
searchers. Clinical consultations are scheduled 1, 3,
and 12 months after surgery. The data acquisition is
presented in Table 2.
Sample size
Based on an overall complication percentage of 65% in
the ORC [3] a sample size of 338 (2 × 169) patients is re-
quired (power 80%; alpha 5%) to detect a decrease in the
overall complication rate of 15%, i.e. from 65 to 50%.
Recruitment
Urologists from 23 Dutch centres are involved in patient
recruitment. Patient information has been designed in
close cooperation with the patient society, i.e. represen-
tatives of the Bladder Cancer Patient Society “Leven met
Blaas- of Nierkanker” are full members of the RACE
project team. Both the support of the Dutch Urology As-
sociation and Bladder Cancer Patient Society “Leven met
Blaas- of Nierkanker” will help us to include sufficient
patients in the trial. Screening and recruitment will con-
tinue until the target population (n = 338) is achieved.
Data collection methods and data management
Questionnaires will be administered web-based or
paper-based, processed and stored digitally using a vali-
dated data management system (eCRF, Research Manager).
Fig. 1 Flowchart RACE study
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Participant application forms (provided by urologists in par-
ticipating centres), medical history, and clinical data will be
registered, processed and stored using eCRF Research Man-
ager. Data will be handled according to the Dutch law
(Dutch Data Protection Act). Data will be anonymized by a
unique identification number.
Statistical methods
Outcomes
Effects on complications, disease free survival, blood trans-
fusion and organ injury will be calculated as rate differences
with 95% confidence intervals. Effects of surgery on quality
of life, pain after surgery, time to return to full activity, op-
erating time and hospital stay will be calculated as mean
differences with 95% confidence intervals. All analyses will
be performed on an intention-to-treat basis. To account for
potential confounders (including confounding by indica-
tion), we will use both multivariate regression models and
propensity score methods. Furthermore, a rule-out ap-
proach will be used for sensitivity analysis [26] to illustrate
how strongly a single unmeasured binary confounder
would have to be associated with both the intervention and
the end point to fully explain eventual significant findings.
Multiple imputation using 10 imputed data sets will be
used to handle missing data.
Cost effectiveness analysis
The economic evaluation will be conducted conform
current guidelines [27]. Primary outcome measures for the
economic evaluation are societal costs, complications, and
quality-adjusted life years (QALYs). To obtain QALYs, the
derived health states from the EQ-5D-5 L are converted
into utility scores. From these utility scores QALYs will be
calculated for each patient using the Area Under the Curve
(AUC) method. Resource use will be measured prospect-
ively on a patient level using medical records and
patient-completed questionnaires. The friction cost-method
will be applied following the Dutch guidelines [27]. Re-
source use will be multiplied with the corresponding unit
costs to obtain total costs for each participating patient.
The Dutch guidelines for costing research will be used [27].
For units of care/resources where no guideline or standard
price is available actual costs will be determined. Costs of
the interventions, RARC and ORC, will be determined
through activity-based costing. For RARC, the cost per pro-
cedure will depend on the anticipated throughput of pa-
tients per year. We will therefore explore a number of
scenarios with different throughput.
An incremental cost-effectiveness ratio (ICER), i.e.
cost per QALY gained, will be computed. Uncertainty
will be determined using the bootstrap method. A
cost-effectiveness acceptability curve will be derived
to visualize the probability of RARC and ORC being
cost-effective, over different thresholds. In addition,
the impact of uncertainty surrounding important pa-
rameters (for example unit costs) on the ICER will be
explored using one-way sensitivity analyses.
While the main purpose of this study involves the com-
parison between RARC and ORC, a third approach is
laparoscopic-assisted cystectomy (LRC). Although this ap-
proach is performed in only one Dutch medical centre
(i.e. Maxima Medical Centre in Veldhoven), it is interest-
ing to additionally explore the added value of RARC and
ORC compared to LRC. During the RACE study, the
Maxima Medical Centre will collect the data as described
above in the patients that are treated with LRC. Because
this involves a small number of patients, decision analytic
modelling will be performed to synthesize data from the
main RACE study with this additional sample. This will
allow us to explore the cost-effectiveness of the three
techniques. The model will be constructed in close
collaboration with clinical experts, and will comply
with the latest guidelines on decision-analytic model-
ling in health care [28].
Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) flow diagram of study enrolment, interventions
and assessments
Study period
Enrolment Allocation Post-allocation Close-out
Timeline 4–6 weeks before Radical Cystectomy Radical Cystectomy 1 m 3 m 6 m 12 m
Timepoint -t1 0 t1 t2 t3 t4
Enrolment:
Eligibility screen X
Informed consent X
Intervention: RARC or ORC X
Assessments:
Quality of Life X X X X X
Patient based healthcare usage X Monthly
Clinical data X X X
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Data monitoring
Participation in the RACE-study carries no risks additional
to those associated with standard care. Therefore, no Data
Monitoring Committee (DMC) is needed. However, the
study is conducted in accordance with principles of Good
Clinical Practice. For this reason, we have developed a
monitoring plan for data collection, aiming for:
1. Full monitoring of informed consents;
2. Monitoring of the first three patients per center. In
case of no violation ad random 10% of patients, to
ensure data quality.
3. Source data verification in 10% of the included
patients.
Ethics and dissemination
Research ethics approval and amendments
The study protocol, amendments, informed consent form
and patient information brochure have been reviewed and
approved by the sponsor (ZonMw, The Netherlands
Organization for Health Research and Development) and
the accredited medical ethics committee (Commission for
Research in Human Subjects, in Dutch: Commissie
Mensgebonden Onderzoek (CMO), region Arnhem –
Nijmegen, the Netherlands). Since the enforcement of the
Centrale Commissie Mensgebonden Onderzoek (CCMO)
External Review Directive in 2012, local medical ethical
committees of local participating centers are no longer in-
volved in reviewing the study protocol of multicenter re-
search in the Netherlands and ethical approval obtained,
covers all participating centers.
Consent or assent
Potential participants will be informed by the urologist.
Informed consent documents of all participants are ob-
tained and co-signed by clinician who provided the pa-
tient information.
Dissemination policy
Results of the RACE study will be communicated to par-
ticipants, healthcare professionals and the public
through newsletters, publications in peer-reviewed jour-
nals and presentations on (inter)national meetings of the
Dutch Urology Association and patient society.
Discussion
Radical cystectomy with pelvic lymphadenectomy and urin-
ary diversion is the standard of care for both high-risk
non-muscle-invasive bladder cancer and muscle-invasive
disease [1]. Due to improved anaesthesia, better surgical
techniques, and centralization of care in high volume cen-
ters, reduction in morbidity and mortality has occurred in
recent years. Furthermore, the ERAS protocol has also
helped to reduce the length of stay and complications [29].
RARC has been suggested to potentially improve the peri-
operative morbidity. However, high-level evidence of any
benefit from RARC over ORC of methodologically sound
clinical studies is lacking. This may reflect the complex na-
ture of this procedure as well as the complex
decision-making process of clinicians selecting therapies,
their experience with the technique under study, and on
the decisions and actions of patients, including whether
they accept or prefer a certain surgical technique. The im-
pact of these issues on effectiveness may be difficult or im-
practical to assess in a traditional RCT, in which treatment
assignments are randomized and may therefore lead to a
bias due to the expertise of the surgeons in a center. So far,
four prospective trials have compared RARC with ORC,
but each of them has been limited by sample size, design,
or their application of RARC with extra-corporeal recon-
struction [11, 13, 14, 30].
A comparative effectiveness trial aims to provide
high-quality evidence to help patients and clinicians make
informed clinical decisions and to assist health systems in
improving the quality and cost-effectiveness of clinical
care. The major strength of our design is that we compare
the preferred treatment strategy (RARC versus ORC) of
several centers. Not only the surgeon, but also the team
and caseload will influence the outcome for patients. With
this comparative effectiveness study we compare out-
comes of standardized procedures performed by surgical
teams of 23 hospitals (12 ORC, 10 RARC and 1 LRC).
The results will provide a valid estimate of the real effect-
iveness in daily clinical practice. Furthermore, we will be
able to study whether the distribution of robotic systems
over hospitals and patient allocation to these hospitals is
indeed more or less random. Nevertheless, we will also
perform propensity score analyses to adjustment for po-
tential confounding (by indication).
Another strength of our study is that only centers that
already performed at least 40 RARC-cases and have a
caseload of at least 20 cases per year can participate in
this study. Several studies have described the learning
curve of RARC, which is estimated to be between 16
and 30 cases [17, 19]. This implies that in our study all
centers have passed the learning curve.
At the time of submission of this manuscript, 273 par-
ticipants have been enrolled in the study. Patient recruit-
ment will continue until September 2018 to achieve the
calculated sample size of 338 participants. Due to our
experiences and the accrual rate so far, we are confident
that we will be able to meet the target sample size and
to quantify the effects of RARC as compared to ORC.
With the results of this study we aim to contribute to
the development of evidence-based guidelines regarding
which of the treatment options (RARC or ORC) is the
most (cost-)effective. When RARC appears to be
cost-effective it might become the standard of care for
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the studied patient population. Patients who met the ex-
clusion criteria (prior extensive abdominal surgery or in-
ability for steep Trendelenburg position) should then be
redirected to experienced centers for open surgery. We
expect that about 75% of the cystectomies can be per-
formed with robotic assistance. For RARC to become
cost-effective and taking into account a minimal case-
load of 45 cases per year due to the learning curve,
centralization seems a prerequisite. We will therefore
take this centralization question into account in our final
analytical decision model and budget impact analysis. If
RARC is not cost-effective, ORC should remain the
standard treatment, which should be advocated through
both international papers, updated guidelines, and vari-
ous websites presenting our results. For ORC we will
also model which centralization option appears to be
most promising.
Moreover, we are currently collaborating with re-
searchers from both the RAZOR and iROC trial to en-
able future data-sharing to perform an individual patient
data meta-analysis as to identify relevant subgroups that
benefit more or less and to improve the power of study-
ing complication rates and survival.
Trial status
Recruitment started in March 2016 and is currently on-
going. A total of 273 patients were enrolled by mid-
March 2018 and we expect to finish inclusion by the
end of 2018. One year followup of last patient and statis-
tical analyses expected by the end of 2019.
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